CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts. As of February 23, 2023, CinCor Pharma, Inc. operates as a subsidiary of AstraZeneca Finance and Holdings Inc..
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2023-03-28 |
2022-12 |
-0.55 |
N/A |
N/A |
N/A |
2022-11-03 |
2022-09 |
-0.59 |
N/A |
N/A |
N/A |
2022-08-08 |
2022-06 |
-0.5 |
N/A |
N/A |
N/A |
2022-05-10 |
2022-03 |
-0.5 |
N/A |
N/A |
N/A |
2022-03-22 |
2021-12 |
-1.56 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-01-12 |
Barclays |
Downgrade |
Overweight |
Equal-Weight |
2023-01-10 |
Morgan Stanley |
Upgrade |
|
Equal-Weight |
2022-12-08 |
Barclays |
Upgrade |
|
Overweight |
2022-12-07 |
Barclays |
Upgrade |
|
Overweight |
2022-11-29 |
Morgan Stanley |
Downgrade |
Overweight |
Equal-Weight |
2022-11-29 |
Oppenheimer |
Downgrade |
Outperform |
Perform |
Date |
Name |
Relation |
Quantity |
Description |
2022-08-14 |
5AM PARTNERS VI, LLC |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2022-01-10 |
COELHO MARY THERESA |
Chief Financial Officer |
0.00 |
Purchase |
2023-01-25 |
DE GARIDEL MARC M P |
Chief Executive Officer |
212.50K |
Stock Award(Grant) |
2023-01-25 |
FREEMAN MASON W |
Officer |
42.60K |
Stock Award(Grant) |
2022-08-10 |
GENERAL ATLANTIC, L.P. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2022-08-10 |
HEALY JAMES I |
Director and Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2022-12-30 |
Sofinnova Investments, Inc. |
6.07M |
176.51M |
13.88% |
2022-12-30 |
5AM Venture Management, LLC |
4.94M |
143.49M |
11.28% |
2022-12-30 |
General Atlantic, L.P. |
4.21M |
122.33M |
9.62% |
2022-12-30 |
Perceptive Advisors Llc |
2.58M |
74.87M |
5.89% |
2022-12-30 |
Adage Capital Partners GP L.L.C. |
1.99M |
57.96M |
4.56% |
2022-12-30 |
Orbimed Advisors LLC. |
1.91M |
55.39M |
4.36% |
Report Date |
Organization |
Position |
Value |
Percentage |
2022-09-29 |
Vanguard Total Stock Market Index Fund |
788.27K |
22.91M |
1.80% |
2022-12-30 |
iShares Russell 2000 ETF |
552.42K |
16.05M |
1.26% |
2022-09-29 |
Price (T.Rowe) New Horizons Fund |
444.71K |
12.92M |
1.02% |
2022-12-30 |
iShares Russell 2000 Value ETF |
260.57K |
7.57M |
0.60% |
2022-09-29 |
Vanguard Extended Market Index Fund |
249.19K |
7.24M |
0.57% |
2022-11-29 |
Fidelity Small Cap Index Fund |
161.52K |
4.69M |
0.37% |